Refractory Multiple Myeloma - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Refractory Multiple Myeloma – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Refractory Multiple Myeloma: Overview
Multiple myeloma is defined as the cancer of plasma cells which are found in the bone marrow and form an important part of the immune system. Relapsed/ Refractory multiple myeloma is a condition which becomes progressive or non-responsive to therapies within 60 days of the last treatment in patients who has achieved some response or gotten better on earlier treatments.
“Refractory Multiple Myeloma - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Multiple Myeloma pipeline landscape is provided which includes the disease overview and Refractory Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth Refractory Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Multiple Myeloma.
Refractory Multiple Myeloma Emerging Drugs Chapters
This segment of the Refractory Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Refractory Multiple Myeloma Emerging Drugs
bb2121: Celgene Corporation
Celgene Corporation’s drug bb-2121, also known as Anti- BCMA CART Cell therapy has reached the preregistration phase of the drug development process. The drug has also been awarded the orphan drug status for multiple myeloma. The drug is a chimeric antigen receptor (CAR) T cell therapy which targets the B-cell maturation antigen (BCMA), expressed on the surface of both normal and malignant cells. The bb2121 cells are thought to have the ability to recognize and bind BCMA on plasma cell surface and inducing their apoptosis.
Nivolumab: Bristol-Myers Squibb
Nivolumab’s a Bristol-Myers Squibb product is in the phase III stage of drug development process for the treatment of RRMM. It is the first PD-1 immune checkpoint inhibitor that enables the body’s immune system to restore anti-tumor immune response. It has become one of the important treatment options for multiple cancers.
Further product details are provided in the report……..
Refractory Multiple Myeloma: Therapeutic Assessment
This segment of the report provides insights about the different Refractory Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Refractory Multiple Myeloma
There are approx. 5+ key companies which are developing the therapies for Refractory Multiple Myeloma. The companies which have their Refractory Multiple Myeloma drug candidates in the mid to advanced stage, i.e. phase III include, Bristol-Myers Squibb and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Refractory Multiple Myeloma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Refractory Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory Multiple Myeloma drugs.
Refractory Multiple Myeloma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Refractory Multiple Myeloma – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Refractory Multiple Myeloma: Overview
Multiple myeloma is defined as the cancer of plasma cells which are found in the bone marrow and form an important part of the immune system. Relapsed/ Refractory multiple myeloma is a condition which becomes progressive or non-responsive to therapies within 60 days of the last treatment in patients who has achieved some response or gotten better on earlier treatments.
“Refractory Multiple Myeloma - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Multiple Myeloma pipeline landscape is provided which includes the disease overview and Refractory Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth Refractory Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Refractory Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve Refractory Multiple Myeloma.
Refractory Multiple Myeloma Emerging Drugs Chapters
This segment of the Refractory Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Refractory Multiple Myeloma Emerging Drugs
bb2121: Celgene Corporation
Celgene Corporation’s drug bb-2121, also known as Anti- BCMA CART Cell therapy has reached the preregistration phase of the drug development process. The drug has also been awarded the orphan drug status for multiple myeloma. The drug is a chimeric antigen receptor (CAR) T cell therapy which targets the B-cell maturation antigen (BCMA), expressed on the surface of both normal and malignant cells. The bb2121 cells are thought to have the ability to recognize and bind BCMA on plasma cell surface and inducing their apoptosis.
Nivolumab: Bristol-Myers Squibb
Nivolumab’s a Bristol-Myers Squibb product is in the phase III stage of drug development process for the treatment of RRMM. It is the first PD-1 immune checkpoint inhibitor that enables the body’s immune system to restore anti-tumor immune response. It has become one of the important treatment options for multiple cancers.
Further product details are provided in the report……..
Refractory Multiple Myeloma: Therapeutic Assessment
This segment of the report provides insights about the different Refractory Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Refractory Multiple Myeloma
There are approx. 5+ key companies which are developing the therapies for Refractory Multiple Myeloma. The companies which have their Refractory Multiple Myeloma drug candidates in the mid to advanced stage, i.e. phase III include, Bristol-Myers Squibb and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Peptides
- Cell Therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Refractory Multiple Myeloma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Refractory Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Refractory Multiple Myeloma drugs.
Refractory Multiple Myeloma Report Insights
- Refractory Multiple Myeloma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Refractory Multiple Myeloma drugs?
- How many Refractory Multiple Myeloma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Refractory Multiple Myeloma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Refractory Multiple Myeloma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Refractory Multiple Myeloma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Bristol-Myers Squibb
- Celgene Corporation
- GlaxoSmithKline
- Regeneron Pharmaceuticals/ Sanofi
- Immunoforge
- Nivolumab
- bb2121
- Belantamab mafodotin
Introduction
Executive Summary
Refractory Multiple Myeloma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Refractory Multiple Myeloma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Refractory Multiple Myeloma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Refractory Multiple Myeloma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
bb2121: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Refractory Multiple Myeloma Key Companies
Refractory Multiple Myeloma Key Products
Refractory Multiple Myeloma- Unmet Needs
Refractory Multiple Myeloma- Market Drivers and Barriers
Refractory Multiple Myeloma- Future Perspectives and Conclusion
Refractory Multiple Myeloma Analyst Views
Refractory Multiple Myeloma Key Companies
Appendix
Executive Summary
Refractory Multiple Myeloma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Refractory Multiple Myeloma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Refractory Multiple Myeloma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Refractory Multiple Myeloma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
bb2121: Celgene Corporation
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Refractory Multiple Myeloma Key Companies
Refractory Multiple Myeloma Key Products
Refractory Multiple Myeloma- Unmet Needs
Refractory Multiple Myeloma- Market Drivers and Barriers
Refractory Multiple Myeloma- Future Perspectives and Conclusion
Refractory Multiple Myeloma Analyst Views
Refractory Multiple Myeloma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Refractory Multiple Myeloma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Refractory Multiple Myeloma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Refractory Multiple Myeloma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Refractory Multiple Myeloma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
